Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice

William A. Banks, John E. Morley, Susan A. Farr, Tulin O. Price, Nuran Ercal, Irving Vidaurreg, Andrew V Schally

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Both deficiency and excess of growth hormone (GH) are associated with increased mortality and morbidity. GH replacement in otherwise healthy subjects leads to complications, whereas individuals with isolated GH deficiency such as Laron dwarfs show increased life span. Here, we determined the effects of treatment with the GH-releasing hormone (GHRH) receptor antagonist MZ-5-156 on aging in SAMP8 mice, a strain that develops with aging cognitive deficits and has a shortened life expectancy. Starting at age 10 mo, mice received daily s.c. injections of 10 μg/mouse of MZ-5-156. Mice treated for 4 mo with MZ-5-156 showed increased telomerase activity, improvement in some measures of oxidative stress in brain, and improved pole balance, but no change in muscle strength. MZ-5-156 improved cognition after 2 mo and 4 mo, but not after 7 mo of treatment (ages 12, 14 mo, and 17 mo, respectively). Mean life expectancy increased by 8 wk with no increase in maximal life span, and tumor incidence decreased from 10 to 1.7%. These results show that treatment with a GHRH antagonist has positive effects on some aspects of aging, including an increase in telomerase activity.

Original languageEnglish
Pages (from-to)22272-22277
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number51
DOIs
StatePublished - Dec 21 2010

Fingerprint

Hormone Antagonists
Growth Hormone-Releasing Hormone
Telomerase
Oxidative Stress
Life Expectancy
Pituitary Dwarfism
Muscle Strength
Cognition
Growth Hormone
Healthy Volunteers
Therapeutics
Morbidity
Injections
Mortality
MZ 5-156
Incidence
Brain
Neoplasms

Keywords

  • Alzheimer's disease
  • Learning
  • Memory
  • Peptide
  • Sarcopenia

ASJC Scopus subject areas

  • General

Cite this

Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice. / Banks, William A.; Morley, John E.; Farr, Susan A.; Price, Tulin O.; Ercal, Nuran; Vidaurreg, Irving; Schally, Andrew V.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 51, 21.12.2010, p. 22272-22277.

Research output: Contribution to journalArticle

Banks, William A. ; Morley, John E. ; Farr, Susan A. ; Price, Tulin O. ; Ercal, Nuran ; Vidaurreg, Irving ; Schally, Andrew V. / Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice. In: Proceedings of the National Academy of Sciences of the United States of America. 2010 ; Vol. 107, No. 51. pp. 22272-22277.
@article{263de0ca989f454b96820e97bb197799,
title = "Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice",
abstract = "Both deficiency and excess of growth hormone (GH) are associated with increased mortality and morbidity. GH replacement in otherwise healthy subjects leads to complications, whereas individuals with isolated GH deficiency such as Laron dwarfs show increased life span. Here, we determined the effects of treatment with the GH-releasing hormone (GHRH) receptor antagonist MZ-5-156 on aging in SAMP8 mice, a strain that develops with aging cognitive deficits and has a shortened life expectancy. Starting at age 10 mo, mice received daily s.c. injections of 10 μg/mouse of MZ-5-156. Mice treated for 4 mo with MZ-5-156 showed increased telomerase activity, improvement in some measures of oxidative stress in brain, and improved pole balance, but no change in muscle strength. MZ-5-156 improved cognition after 2 mo and 4 mo, but not after 7 mo of treatment (ages 12, 14 mo, and 17 mo, respectively). Mean life expectancy increased by 8 wk with no increase in maximal life span, and tumor incidence decreased from 10 to 1.7{\%}. These results show that treatment with a GHRH antagonist has positive effects on some aspects of aging, including an increase in telomerase activity.",
keywords = "Alzheimer's disease, Learning, Memory, Peptide, Sarcopenia",
author = "Banks, {William A.} and Morley, {John E.} and Farr, {Susan A.} and Price, {Tulin O.} and Nuran Ercal and Irving Vidaurreg and Schally, {Andrew V}",
year = "2010",
month = "12",
day = "21",
doi = "10.1073/pnas.1016369107",
language = "English",
volume = "107",
pages = "22272--22277",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "51",

}

TY - JOUR

T1 - Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice

AU - Banks, William A.

AU - Morley, John E.

AU - Farr, Susan A.

AU - Price, Tulin O.

AU - Ercal, Nuran

AU - Vidaurreg, Irving

AU - Schally, Andrew V

PY - 2010/12/21

Y1 - 2010/12/21

N2 - Both deficiency and excess of growth hormone (GH) are associated with increased mortality and morbidity. GH replacement in otherwise healthy subjects leads to complications, whereas individuals with isolated GH deficiency such as Laron dwarfs show increased life span. Here, we determined the effects of treatment with the GH-releasing hormone (GHRH) receptor antagonist MZ-5-156 on aging in SAMP8 mice, a strain that develops with aging cognitive deficits and has a shortened life expectancy. Starting at age 10 mo, mice received daily s.c. injections of 10 μg/mouse of MZ-5-156. Mice treated for 4 mo with MZ-5-156 showed increased telomerase activity, improvement in some measures of oxidative stress in brain, and improved pole balance, but no change in muscle strength. MZ-5-156 improved cognition after 2 mo and 4 mo, but not after 7 mo of treatment (ages 12, 14 mo, and 17 mo, respectively). Mean life expectancy increased by 8 wk with no increase in maximal life span, and tumor incidence decreased from 10 to 1.7%. These results show that treatment with a GHRH antagonist has positive effects on some aspects of aging, including an increase in telomerase activity.

AB - Both deficiency and excess of growth hormone (GH) are associated with increased mortality and morbidity. GH replacement in otherwise healthy subjects leads to complications, whereas individuals with isolated GH deficiency such as Laron dwarfs show increased life span. Here, we determined the effects of treatment with the GH-releasing hormone (GHRH) receptor antagonist MZ-5-156 on aging in SAMP8 mice, a strain that develops with aging cognitive deficits and has a shortened life expectancy. Starting at age 10 mo, mice received daily s.c. injections of 10 μg/mouse of MZ-5-156. Mice treated for 4 mo with MZ-5-156 showed increased telomerase activity, improvement in some measures of oxidative stress in brain, and improved pole balance, but no change in muscle strength. MZ-5-156 improved cognition after 2 mo and 4 mo, but not after 7 mo of treatment (ages 12, 14 mo, and 17 mo, respectively). Mean life expectancy increased by 8 wk with no increase in maximal life span, and tumor incidence decreased from 10 to 1.7%. These results show that treatment with a GHRH antagonist has positive effects on some aspects of aging, including an increase in telomerase activity.

KW - Alzheimer's disease

KW - Learning

KW - Memory

KW - Peptide

KW - Sarcopenia

UR - http://www.scopus.com/inward/record.url?scp=78650642919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650642919&partnerID=8YFLogxK

U2 - 10.1073/pnas.1016369107

DO - 10.1073/pnas.1016369107

M3 - Article

C2 - 21135231

AN - SCOPUS:78650642919

VL - 107

SP - 22272

EP - 22277

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 51

ER -